Search clinical trials for: Coagulation factor

Total 38394 results

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

China
Octapharma

Terminated

Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq (PREVAIL)

Hemophilia A

Canada
Hasan Kalyoncu University

Unknown

Effect of Exercise in Pediatric Hemophilia

Hemophilia Arthropathy | Hemophilia A, Severe

Turkey
AryoGen Pharmed Co.

Completed

Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency

Factor VII Deficiency

Iran, Islamic Republic of
Fred Hutchinson Cancer Center

Completed

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Primary Myelofibrosis | Essential Thrombocythemia | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated... and other conditions

United States
Peking University People's Hospital
Beijing Tongren Hospital; Beijing Hospital; Navy General Hospital, Beijing

Unknown

The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Immune Thrombocytopenia

China
Octapharma

Completed

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

Severe Hemophilia A

Canada, United States, France, Spain, Ukraine, United Kingdom, Belarus, Georgia, Germany, India, Italy, Moldova, Republic of, Morocco, Poland, Portugal, Russian Federation, Slovenia
Octapharma

Completed

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

Severe Hemophilia A

Bulgaria, Poland, Hungary, Romania, Russian Federation
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

Severe Hemophilia A

United States, United Kingdom, Spain, Hong Kong, Israel, New Zealand, Sweden, Australia, Brazil, Japan, Austria, Belgium, Italy, India, Switzerland, Canada, France, Germany, South Africa
Children's Mercy Hospital Kansas City

Terminated

A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipuncture (CVL#2)

Hemophilia A | Hemophilia B | Hemophilia | Factor IX Deficiency | Factor VIII Deficiency

United States
Bayer

Completed

Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)

Hemophilia A

Bulgaria
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A (ASPIRE)

Hemophilia A

United States, Canada, Italy, Australia, Austria, Belgium, Brazil, France, Germany, Hong Kong, India, Ireland, Israel, Japan, Netherlands, New Zealand, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
Bioverativ Therapeutics Inc.

Completed

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Severe Hemophilia A

United States, Hong Kong, Israel
Bioverativ Therapeutics Inc.

Completed

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

Severe Hemophilia A

United States, United Kingdom, Australia
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale (Elevate)

Severe Hemophilia A

United States, Australia, New Zealand
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A (Kids ALONG)

Hemophilia A

United States, Poland, United Kingdom, Netherlands, South Africa, Hong Kong, Australia, Ireland
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B (Kids B-LONG)

Hemophilia B

United States, United Kingdom, South Africa, Netherlands, Ireland, Australia
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Terminated

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes (FORWARD)

Hemophilia A | Hemophilia B

United States
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum; Syntonix Pharmaceuticals, Inc.

Completed

Phase I/IIa Study of FIXFc in Hemophilia B Patients

Hemophilia B

United States
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

Severe Hemophilia B

Sweden, United States, France, Italy, Russian Federation, United Kingdom, Germany, China, Poland, Japan, Australia, Brazil, Canada, India, South Africa, Hong Kong, Belgium
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B (B-YOND)

Severe Hemophilia B

United States, Italy, Belgium, Australia, Brazil, Hong Kong, India, Ireland, Japan, South Africa, United Kingdom, Netherlands, Sweden, Canada, Poland, China, France, Germany
City of Hope Medical Center
CSL Behring; Grifols Therapeutics LLC; Grifols Biologicals, LLC; Charta Foundation and other collaborators

Withdrawn

Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive (RESIST NAIVE)

Severe Hemophilia A
Bayer

Terminated

Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

Hemophilia A and B

Australia, United Kingdom, Taiwan, Japan, Korea, Republic of, Austria, Bulgaria, Hungary, Italy, France, New Zealand
Bayer

Completed

Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A." (POTTER 10)

Hemophilia A

Italy
Pfizer

Withdrawn

Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis

Hemophilia A
ISU Abxis Co., Ltd.
Catalyst Biosciences

Completed

Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients

Hemophilia B

Korea, Republic of
University Health Network, Toronto

Unknown

Factor Replacement in Surgery (FARES)

Bleeding in Cardiac Surgery

Canada
National Taiwan University Hospital

Unknown

The Effectiveness of Recombinant Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients

Hemophilia

Taiwan
David Gomez Almaguer

Unknown

Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia

Thrombotic Thrombocytopenic Purpura | Immune Thrombocytopenia

Mexico
LifeBridge Health
Janssen Scientific Affairs, LLC

Unknown

Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy

Coronary Artery Disease | Peripheral Artery Disease

United States
The Hospital for Sick Children

Completed

Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A

Hemophilia A

Canada
Tri-Service General Hospital

Completed

Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy

Hemophilia | Hemophilic Arthropathy
McMaster University
GlaxoSmithKline; Novartis; Hamilton Health Sciences Corporation

Completed

A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients

Immune Thrombocytopenic Purpura

Canada, Netherlands
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

Healthy

United States
Semmelweis University

Completed

Individualized Multimodal Hemostasis Evaluation Pyramid (IMHOTEP)

Blood Loss, Postoperative | Liver Transplant | Hemostatic Disorder

Hungary
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

Healthy

United States
Bayer

Completed

Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

Hemophilia A

Belgium, New Zealand, Netherlands, Greece, United Kingdom, Austria, United States, Italy, Romania, Bulgaria, Canada, Israel, Poland, Lithuania, Norway, Argentina, Spain
Institute of Hematology & Blood Diseases Hospital
Henan Cancer Hospital; Nantong University; Tianjin Medical University Second... and other collaborators

Unknown

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Primary Immune Thrombocytopenia (ITP)

China
Erasmus Medical Center
Shire; CSL Behring; Stichting Haemophilia (Dutch Haemophilia Foundation)

Unknown

Von Willebrand Disease in the Netherlands (WiN-Pro)

Von Willebrand Disease

Netherlands
Samsung Medical Center

Completed

Safety and Efficacy of Edoxaban in Thoracoscopic Ablation

Atrial Fibrillation | Anticoagulants and Bleeding Disorders

Korea, Republic of
Novo Nordisk A/S

Completed

Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (guardian TM 7)

Congenital Bleeding Disorder | Haemophilia A

China
Eio Biomedical Ltd.

Completed

Evaluation of the Feasibility, Safety, Initial Efficacy and Clinical Usability of FuseX Anti-Adhesion System

Reduction of Postoperative Adhesions

Lithuania
Karadeniz Technical University

Completed

Raloxifene on Coagulation System in the Postmenopausal Women

Postmenopausal Women | Raloxifene
Octapharma

Completed

Octaplas Pediatric Plasma Replacement Trial

Cardiac Surgery | Liver Dysfunction | Coagulopathy | Liver Surgery

United States
Pfizer

Completed

A Gene Therapy Study for Hemophilia B

Hemophilia B

United States, Australia
PTC Therapeutics
Genzyme, a Sanofi Company

Terminated

Study of Ataluren (PTC124) in Hemophilia A and B

Hemophilia A | Hemophilia B

United States, Canada, France, Italy
Patricia Duque González

Completed

Impact of Acquired FXIII Deficiency on Morbidity and Mortality

Acquired Factor XIII Deficiency Disease

Spain
University of California, Davis

Terminated

INdividualized ITI Based on Fviii(ATE) Protection by VWF (INITIATE)

Hemophilia A | Hemophilia A With Inhibitor

United States
Bayer

Completed

Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients

Hemophilia

Turkey
Boston Children's Hospital
Terrana ITP Research Fund

Completed

ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP (ICON1)

Immune Thrombocytopenia

United States, Canada

Search clinical trials for: Coagulation factor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations